Despite the presence of novel and more potent P2Y12 receptor blockers on the market for more than five years, clopidogrel is still often used in patients with acute coronary syndrome undergoing percutaneous coronary intervention. It is known that clopidogrel exhibits variable platelet inhibition which affects patient outcome. So called clopidogrel resistance or high on-treatment platelet reactivity on clopidogrel has interested many since it was first described more than ten years ago. How relevant is it today? What do we really need to know about clopidogrel resistance?

In this presentation, an overview of relevant studies will be highlighted as well as experts’ position on this phenomenon and future perspectives in antiplatelet management.

KEYWORDS: clopidogrel resistance, platelet reactivity, platelet function tests, coronary artery disease.


ADDRESS FOR CORRESPONDENCE: Jure Samardžić, Klinički bolnički centar Zagreb, Kišpatićeva 12, HR-10000 Zagreb, Croatia. Phone: +385-1-236-7467 / E-mail: jure.samardzic@gmail.com

ORCID: Jure Samardžić, http://orcid.org/0000-0002-9346-6402

LITERATURE